Inhibition of Pathogenic Biofilms on Teeth and Implants

Reference Number TO 02-00226

 

The Challenge

Streptococcus mutans is a clinically important contributor to pathogenic biofilms generating caries, endocarditis or other infectious diseases. These biofilms are growing preferably under anaerobic conditions like on surfaces of implants within the human or animal body. As in clinical infections involving biofilm formation an increased resistance against antibiotics is generally found, the demand for alternative therapeutic strategies is high. 

 

 

The Technology

The invention relates to carolacton as a pharmaceutical composition. Carolacton is a natural small molecule with a unique chemical structure produced by myxobacteria of the genus Sorangium. Carolacton is very effective in the reduction or prevention of bacterial biofilms which are generated on natural or synthetic surfaces, e.g. on the surface of teeth in the form of dental plaque, as well as on implant surfaces, e.g. on the surface of stents, artificial joints, heartvalves or vessels. Carolacton has no relevant antibiotic activity, but still has the ability to inhibit the formation of biofilms at very low concentrations. This could be exemplified in biofilms containing Streptococcus mutans, a clinically important contributor to pathogenic biofilms.

Commercial Opportunity

In-licensing of IP for the development of a drug for the treatment or prevention of pathogenic biofilms within the human or animal body. Cooperation for further development is also possible.

Developmental Status

Exemplified medical effectiveness in biofilms containing Streptococcus mutans.

Patent Situation

A European Patent Application filed in 2007 is pending (EP07115738.2). An international application will follow.

Download PDF

 

Contact:

Dr. Sabina Heim
Technology Manager
Ascenion GmbH

T: +49 (0)0531 6181 2090
F: +49 (0)0531 6181 2098
heim(at)ascenion.de